Skip to main content

Anti-Rheumatic Rx

    On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these as their favorite reports: DAS-28 independently associated survival in RA-ILD. As I keep saying, treating the rheumatoid…
    Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis. Abstract 1424 – Dr. Hermine…
    RT @ericdeinmd: Thank you @AhmadSherbini for discussing his #ACR21 research on @RheumNow on Abs#1444 - Can we predict wh
    2 years ago
    Thank you @AhmadSherbini for discussing his #ACR21 research on @RheumNow on Abs#1444 - Can we predict which patients are most likely to have nausea or alopecia intolerance to MTX? https://t.co/I5WmCECq7v
    RT @uptoTate: Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use
    Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use in Caucasians w/ PsA vs DMARDs in black PsA pts. View Abs 1780 for other relevant findings. #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/0uKsa8i0bG https://t.co/R9YkxYqXws
    RT @doctorRBC: Methotrexate did not improve Ustekinumab efficacy in tx of PsA
    ⭐️Addition of MTX did not improve dact
    Methotrexate did not improve Ustekinumab efficacy in tx of PsA ⭐️Addition of MTX did not improve dactylitis, enthesitis, skin, QoL or function #ACR21 #ACRBest @RheumNow Abs#L12 https://t.co/6dxWPNskou https://t.co/BnzH8PfaMV
    RT @RichardPAConway: No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthr
    No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthritis, enthesitis, dactylitis, skin, QoL or function. Abstr#L12 #ACR21 @RheumNow https://t.co/iojKLqRb06
    ×